Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates by Lee, Hyun Myung et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ienz20
Journal of Enzyme Inhibition and Medicinal Chemistry
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ienz20
Pyridinium-2-carbaldoximes with quinolinium
carboxamide moiety are simultaneous
reactivators of acetylcholinesterase and
butyrylcholinesterase inhibited by nerve agent
surrogates
Hyun Myung Lee , Rudolf Andrys , Jakub Jonczyk , Kyuneun Kim , Avinash
G. Vishakantegowda , David Malinak , Adam Skarka , Monika Schmidt ,
Michaela Vaskova , Kamil Latka , Marek Bajda , Young-Sik Jung , Barbara
Malawska & Kamil Musilek
To cite this article: Hyun Myung Lee , Rudolf Andrys , Jakub Jonczyk , Kyuneun Kim , Avinash
G. Vishakantegowda , David Malinak , Adam Skarka , Monika Schmidt , Michaela Vaskova ,
Kamil Latka , Marek Bajda , Young-Sik Jung , Barbara Malawska & Kamil Musilek (2021)
Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators
of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates, Journal of
Enzyme Inhibition and Medicinal Chemistry, 36:1, 437-449, DOI: 10.1080/14756366.2020.1869954
To link to this article:  https://doi.org/10.1080/14756366.2020.1869954
© 2021 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 19 Jan 2021. Submit your article to this journal 
Article views: 440 View related articles 
View Crossmark data
RESEARCH PAPER
Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are
simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase
inhibited by nerve agent surrogates
Hyun Myung Leea,b , Rudolf Andrysc , Jakub Jonczykd , Kyuneun Kima,b ,
Avinash G. Vishakantegowdaa,b , David Malinakc , Adam Skarkac , Monika Schmidtc , Michaela Vaskovac
, Kamil Latkad , Marek Bajdad , Young-Sik Junga,b , Barbara Malawskad and Kamil Musilekc
aDivision of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea; bDepartment of Medicinal
Chemistry and Pharmacology, Daejeon, Republic of Korea; cDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec
Kralove, Czech Republic; dDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow,
Poland
ABSTRACT
The pyridinium-2-carbaldoximes with quinolinium carboxamide moiety were designed and synthesised as
cholinesterase reactivators. The prepared compounds showed intermediate-to-high inhibition of both chol-
inesterases when compared to standard oximes. Their reactivation ability was evaluated in vitro on human
recombinant acetylcholinesterase (hrAChE) and human recombinant butyrylcholinesterase (hrBChE) inhib-
ited by nerve agent surrogates (NIMP, NEMP, and NEDPA) or paraoxon. In the reactivation screening, one
compound was able to reactivate hrAChE inhibited by all used organophosphates and two novel com-
pounds were able to reactivate NIMP/NEMP-hrBChE. The reactivation kinetics revealed compound 11 that
proved to be excellent reactivator of paraoxon-hrAChE better to obidoxime and showed increased reacti-
vation of NIMP/NEMP-hrBChE, although worse to obidoxime. The molecular interactions of studied reacti-
vators were further identified by in silico calculations. Molecular modelling results revealed the importance
of creation of the pre-reactivation complex that could lead to better reactivation of both cholinesterases
together with reducing particular interactions for lower intrinsic inhibition by the oxime.
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Organophosphates (OPs) in the form of nerve agents (e.g. sarin,
VX tabun) or pesticides (e.g. paraoxon as more toxic metabolite of
parathion) are serious threat or health problem in a global per-
spective1. They irreversibly inhibit acetylcholinesterase (AChE),
butyrylcholinesterase (BChE), or other esterases responsible for
crucial processes in the organism2. However, the most acute for
human health is AChE inhibition. In principle, OP is irreversibly
bound to Ser203 (hAChE) and causes accumulation of acetylcho-
line on the synapses. The synaptic overstimulation with conse-
quent nicotinic, muscarinic, or central effects may lead to serious
injury or death3.
The OP intoxication can be treated by cholinesterase antidotes.
They are usually composed of parasympatholytic agent (e.g. atro-
pine and avizafone), cholinesterase reactivator (e.g. pralidoxime 1,
obidoxime 2, and asoxime 3; Figure 1), and anticonvulsant (e.g.
diazepam)4. The symptomatic treatment is mediated by parasym-
patholytics and anticonvulsants. However, the causal treatment is
done by cholinesterase reactivator with oxime moiety. The oxime
functional group is able to transform into nucleophilic oximate
anion under physiological pH 7.4 and split the OP moiety from
AChE active site via formation of phosphylated oxime that is fur-
ther degraded or excreted5. This way, OP is detoxified and AChE
function is restored.
The AChE reactivators (so called oximes) have very variable
ability to detoxify various OP species6. In fact, there is no optimal
oxime able to treat all OP intoxications. In clinical praxis, the
charged oximes are used (e.g. Figure 1). Their biggest advantage
consists in a high water solubility that allows their rapid distribu-
tion after i.m. administration and a high clearance from organism
via urine7. However, their disadvantage is very limited CNS distri-
bution and thus limited possibility to reactivate brain AChE8. To
overlap this issue, there are recent studies that are focussed on
encapsulation of charged reactivators into, e.g. solid lipid nanopar-
ticles that were found to improve reactivation of brain AChE9.
For this reason, various uncharged oximes or non-oxime reacti-
vators were introduced and they were recently reviewed10. Their
advantage should consist in higher CNS permeability and thus
more rapid reactivation of brain AChE. Some studies suggested
the uncharged oximes are bioavailable in CNS, but the rapid
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elimination from the CNS was also proved11,12. In contrast, the
non-oxime reactivators failed to provide effective OP detoxifica-
tion to date13.
In the last decade, a particular attention was focussed on
reactivation of BChE as well. The BChE is natural bioscavenger
that is binding OP without serious physiological consequences. On
this basis, the pseudo-catalytic scavenger concept was proposed14.
Such antidote should consist of hBChE and its effective reactivator,
which would allow to repeatedly restore BChE scavenging func-
tion. For this purpose, the purification system for truly human
BChE from human plasma was developed15. However, there is lack
of effective BChE reactivators since the charged or uncharged
oximes were designed to primarily reactivate AChE. Recently, the
promising and simultaneous AChE and BChE reactivation was
found for e.g. charged chlorinated oximes16,17.
In this work, we were focussed on design, synthesis and
detailed in vitro/in silico evaluation of charged pyridinium-2-carbal-
doximes on human recombinant AChE (hrAChE) and human
recombinant BChE (hrBChE) inhibited by nerve agent surrogates
(NIMP, NEMP, and NEDPA) and pesticide metabolite paraoxon. The
novel oximes were designed from formerly effective and simultan-
eous AChE/BChE reactivators K117 or K127 (Figure 2) with




Unless otherwise stated, all commercially available reagents and
solvents were used without further purification. DMF, CH3CN,
CH2Cl2, and THF were dried by using a JC Meyer solvent purifica-
tion system prior to use. Analytical thin layer chromatography
(TLC) was performed on Merck silica gel 60 F254 plates. Column
chromatography was performed on silica gel 60 (230–400 mesh)
using proper eluent systems. 1H NMR was recorded on Bruker 500
instrument at 500MHz and 13C NMR was recorded at 125MHz.
Chemical shifts were quoted in parts per million (ppm) referenced
to the appropriate solvent peak or 0.0 ppm for tetramethylsilane.
The following abbreviations were used to describe peak splitting
patterns when appropriate: br¼broad, s¼ singlet, d¼doublet,
t¼ triplet, q¼quartette, dd¼doublet of doublet, td¼ triplet of
doublet, ddd¼doublet of doublet of doublet, and m¼multiplet.
Coupling constants, J, were reported in hertz unit (Hz). 13C NMR
was recorded on Bruker Avance instrument at 125MHz and fully
decoupled by broad band proton decoupling. Chemical shifts are
given in ppm referenced to the centre of a heptate at
40.01–39.01 ppm of DMSO-d6. High resolution mass spectra
(HRMS) were obtained by using EI ionisation and ESI ionisation
methods. All compounds assayed were >95% pure, as determined
by UPLC analysis conducted on Waters Acquity UPLC H-Class sys-
tem with photodiode array (PDA) detector using a reverse-phase
column with a linear H2O/CH3CN gradient system, 10% to 90%
CH3CN in H2O.
2.1.2. Synthesis of pyridinium-2-carbaldoximes with quinolinium
carboxamide moiety
2.1.2.1. Synthesis of carboxamide precursors. Quinoline-3-carboxa-
mide (4) was purchased from Combi-Blocks. Quinoline-4-carboxa-
mide (5): To a mixture of quinoline-4-carboxylic acid (6.00 g,
37mmol) in CH2Cl2 (690mL) was added nine drops of DMF at
0 C, followed by oxalyl chloride (16mL) dropwise. The resulting
reaction was stirred at room temperature (r.t.) overnight, and then
concentrated in vacuo. The crude mixture was dissolved in THF
Figure 1. Standard acetylcholinesterase reactivators used as the causal antidotes.
Figure 2. Molecular design of novel pyridinium-2-carbaldoximes with quinolinium carboxamide moiety.
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(300mL) and ammonia gas was added to the solution at 0 C.
After 1 h, the reaction mixture was concentrated in vacuo, filtered
and washed with water to give the desired product (3.96 g, 66%).
1H NMR (500MHz, DMSO-d6) d 8.97 (d, J¼ 4.2 Hz, 1H), 8.26 (s, 1H),
8.22 (d, J¼ 8.4 Hz, 1H), 8.08 (d, J¼ 8.4 Hz, 1H), 7.93 (s, 1H), 7.81 (t,
J¼ 7.6 Hz, 1H), 7.68 (t, J¼ 7.6 Hz, 1H), 7.57 (d, J¼ 4.2 Hz, 1H).
Quinoline-5-carboxamide (6) was purchased from AA blocks.
Quinoline-6-carboxamide (7): To a mixture of quinoline-6-carboxylic
acid (12.8 g, 74mmol) in CH2Cl2 (740mL) was added 20 drops of
DMF at 0 C, followed by oxalyl chloride (32mL) dropwise. The
resulting reaction was stirred at r.t. overnight, and then concen-
trated in vacuo. The crude mixture was dissolved in THF (600mL)
and ammonia gas was added to the solution at 0 C. After 1 h, the
reaction mixture was concentrated in vacuo, filtered and washed
with water to give the desired product (6.0 g, 47%). 1H NMR
(500MHz, DMSO-d6) d 8.99 (dd, J¼ 4.2, 1.7 Hz, 1H), 8.58 (d,
J¼ 1.5 Hz, 1H), 8.52–8.43 (m, 1H), 8.29 (s, 1H), 8.22 (dd, J¼ 8.8,
1.9 Hz, 1H), 8.07 (d, J¼ 8.8 Hz, 1H), 7.62 (dd, J¼ 8.3, 4.2 Hz, 2H).
Quinoline-7-carboxamide (8): To a mixture of quinoline-7-car-
boxylic acid (0.50mg, 2.9mmol) in CH2Cl2 (29mL, 0.1 M) was
added one drops of DMF at 0 C, followed by oxalyl chloride
(0.4mL, 5mmol) dropwise. The resulting reaction was stirred at r.t.
for 1 h, and then concentrated in vacuo. The crude mixture was
dissolved in NH4OH (50mL) and stirred at r.t. for 0.5 h. The reac-
tion mixture was concentrated in vacuo, added with NaHCO3 and
extracted with EA. The combined organic layers were washed with
brine, dried over Na2SO4, filtered and concentrated in vacuo to
give the desired product (371mg, 74%). 1H NMR (500MHz, DMSO-
d6) d 8.99 (dd, J¼ 4.2, 1.7 Hz, 1H), 8.58 (s, 1H), 8.43 (dd, J¼ 8.3,
0.9 Hz, 1H), 8.29 (s, 1H), 8.05 (d, J¼ 1.0 Hz, 2H), 7.62 (dd, J¼ 8.3,
4.2 Hz, 2H).
2.1.2.2. Synthesis of monoquaternary precursor. 1-(5-Bromopentyl)-
2-((hydroxyimino)methyl)pyridin-1-ium bromide (9). 1,5-
Dibromopentane (84mL, 615mmol) was dissolved in MeCN
(373mL, 0.55 M) and added 2-pyridinealdoxime (25 g, 205mmol).
The reaction mixture was stirred at 85 C for 75 h. The reaction
mixture was cooled to r.t. and removed the solvent. The crude
mixture was dissolved in MeOH and silica gel (10 g) was added to
the crude mixture. The solution was stirred at r.t. for 30min and
concentrated in vacuo. The solid was packing with silica gel and
purified by silica gel column chromatography. After further purifi-
cation by silica gel column chromatography and recrystallisation
in acetone/MeOH to give the desired product (7.46 g, 13.4%). 1H
NMR (500MHz, DMSO-d6) d 13.14 (s, 1H), 9.10 (d, J ¼ 6.0 Hz, 1H),
8.89–8.71 (m, 1H), 8.56 (t, J ¼ 7.9 Hz, 1H), 8.41 (dd, J ¼ 8.2 Hz, 1H),
8.12 (t, J ¼ 6.2 Hz, 1H), 4.89–4.66 (m, 2H), 3.53–3.52 (m, 2H),
2.00–1.65 (m, 4H), 1.60–1.37 (m, 2H). 13C NMR (125MHz, DMSO-d6)
d 146.77, 146.00, 145.62, 141.46, 127.48, 125.93, 57.57, 34.81,
31.45, 29.40, and 24.02. HRMS calculated for C11H16BrN2O
þ
271.0441 [M–H]þ; found: m/z 271.0451.
2.1.2.3. Synthesis of final bisquaternary salts. 3-Carbamoyl-1-(5-(2-
((hydroxyimino)methyl)pyridin-1-ium-1-yl)pentyl)quinolin-1-ium brom-
ide (10). 1-(5-Bromopentyl)-2-((hydroxyimino)methyl)pyridin-1-ium
bromide (736mg, 2.09mmol) and quinoline-3-carboxamide
(300mg, 1.74mmol) were dissolved in DMF (17mL). The reaction
mixture was stirred at 85 C for 144 h. Acetone was poured into
the reaction mixture and keep in refrigerator overnight. The solid
was filtered and washed with acetone to give the desired product
(170mg, 17%). 1H NMR (500MHz, DMSO-d6) d 13.14 (s, 1H), 10.07
(s, 1H), 9.80 (s, 1H), 9.14 (d, J¼ 6.2 Hz, 1H), 8.79 (s, 1H), 8.75–8.65
(m, 2H), 8.57 (q, J¼ 8.1 Hz, 2H), 8.45–8.32 (m, 2H), 8.22 (s, 1H), 8.13
(t, J¼ 7.4 Hz, 2H), 5.15 (t, J¼ 7.4 Hz, 2H), 4.78 (t, J¼ 7.7 Hz, 2H),
2.26–1.97 (m, 2H), 1.99–1.72 (m, 2H), and 1.68–1.35 (m, 2H). 13C
NMR (125MHz, DMSO-d6) d 163.14, 149.20, 146.75, 145.98, 145.81,
145.21, 141.44, 141.37, 137.85, 136.97, 131.74, 130.46, 128.76,
127.67, 127.45, 125.87, 57.51, 57.29, 29.64, 28.80, and 22.33. HRMS
calculated for C21H24N4O2
2þ 363.1888 [M–H]þ; found: m/z
363.1881.
4-Carbamoyl-1-(5-(2-((hydroxyimino)methyl)pyridin-1-ium-1-yl)pen-
tyl)quinolin-1-ium bromide (11). 1-(5-Bromopentyl)-2-((hydroxyimi-
no)methyl)pyridin-1-ium bromide (736mg, 2.09mmol) and
quinoline-4-carboxamide (300mg, 1.74mmol) were dissolved in
DMF (17mL). The reaction mixture was stirred at 85 C for 144 h.
Acetone was poured into the reaction mixture and keep in
refrigerator overnight. The solid was filtered and washed with
acetone to give the desired product (65mg, 7%). 1H NMR
(500MHz, DMSO-d6) d 13.14 (s, 1H), 10.07 (s, 1H), 9.80 (s, 1H), 9.14
(d, J¼ 6.2 Hz, 1H), 8.79 (s, 1H), 8.75–8.65 (m, 2H), 8.57 (q,
J¼ 8.1 Hz, 2H), 8.45–8.32 (m, 2H), 8.22 (s, 1H), 8.13 (t, J¼ 7.4 Hz,
2H), 5.15 (t, J¼ 7.4 Hz, 2H), 4.78 (t, J¼ 7.7 Hz, 2H), 2.26–1.97 (m,
2H), 1.99–1.72 (m, 2H), and 1.68–1.35 (m, 2H). 13C NMR (125MHz,
DMSO-d6) d 165.89, 151.76, 149.98, 146.91, 145.91, 145.21, 141.36,
137.88, 135.71, 130.61, 127.93, 127.46, 126.04, 125.80, 119.63,
119.41, 57.51, 57.30, 29.64, 28.85, and 22.34. HRMS calculated for
C21H24N4O2
2þ 363.1888 [M–H]þ; found: m/z 363.1880.
5-Carbamoyl-1-(5-(2-((hydroxyimino)methyl)pyridin-1-ium-1-yl)pen-
tyl)quinolin-1-ium bromide (12). 1-(5-Bromopentyl)-2-((hydroxyimi-
no)methyl)pyridin-1-ium bromide (736mg, 2.09mmol) and
quinoline-4-carboxamide (300mg, 1.74mmol) were dissolved in
DMF (17mL). The reaction mixture was stirred at 85 C for 144 h.
Acetone was poured into the reaction mixture and keep in
refrigerator overnight, then filtered. The solid was put in MeCN at
85 C for overnight to get the desired product (147mg, 13%). 1H
NMR (500MHz, DMSO-d6) d 13.20 (s, 1H), 9.64 (dd, J¼ 5.9, 1.4 Hz,
1H), 9.55–9.48 (m, 1H), 9.07 (dd, J¼ 6.3, 1.4 Hz, 1H), 8.76 (s, 1H),
8.72 (d, J¼ 9.1 Hz, 1H), 8.56 (td, J¼ 7.9, 1.4 Hz, 1H), 8.47 (s, 1H),
8.40 (dd, J¼ 8.2, 1.6 Hz, 1H), 8.32–8.25 (m, 1H), 8.22 (dd, J¼ 8.8,
5.8 Hz, 1H), 8.18 (d, J¼ 7.1 Hz, 1H), 8.13–8.01 (m, 2H), 5.10 (t,
J¼ 7.5 Hz, 2H), 4.74 (t, J¼ 7.6 Hz, 2H), 2.12–1.97 (m, 2H), 1.93–1.85
(m, 2H), and 1.55–1.42 (m, 2H). 13C NMR (125MHz, DMSO-d6) d
168.30, 150.44, 147.23, 146.53, 145.74, 145.50, 141.92, 138.08,
136.62, 135.12, 129.34, 127.97, 127.44, 126.41, 123.26, 121.47,
57.99, 30.13, 29.33, and 22.77. HRMS calculated for C21H24N4O2
2þ
363.1888 [M–H]þ; found: m/z 363.1879.
6-Carbamoyl-1-(5-(2-((hydroxyimino)methyl)pyridin-1-ium-1-yl)pen-
tyl)quinolin-1-ium bromide (13). 1-(5-Bromopentyl)-2-((hydroxyimi-
no)methyl)pyridin-1-ium bromide (500mg, 1.42mmol) and
quinoline-6-carboxamide (196mg, 1.14mmol) were dissolved in
DMF (14mL). The reaction mixture was stirred at 85 C for 144 h.
Acetone was poured into the reaction mixture and keep in
refrigerator overnight. The solid was filtered and washed with
acetone to give the desired product (40mg, 6.7%). 1H NMR
(500MHz, DMSO-d6) d 13.16 (s, 1H), 9.68 (d, J ¼ 5.6 Hz, 1H), 9.37
(d, J ¼ 8.3 Hz, 1H), 9.09 (d, J ¼ 6.1 Hz, 1H), 9.00 (s, 1H), 8.78 (s,
1H), 8.72 (d, J ¼ 9.3 Hz, 1H), 8.63 (d, J ¼ 9.2 Hz, 1H), 8.57 (t, J
¼ 7.8 Hz, 1H), 8.51 (s, 1H), 8.42 (d, J ¼ 7.7 Hz, 1H), 8.32–8.23 (m,
1H), 8.12 (t, J ¼ 6.6 Hz, 1H), 7.91 (s, 1H), 5.10 (t, J ¼ 7.2 Hz, 2H),
4.75 (t, J ¼ 7.4 Hz, 2H), 2.16–1.98 (m, 2H), 1.97–1.81 (m, 2H), and
1.61–1.35 (m, 2H). 13C NMR (125MHz, DMSO-d6) d 165.75, 150.77,
148.30, 146.77, 145.20, 141.38, 138.45, 134.82, 133.52, 130.36,
129.32, 127.45, 125.84, 122.84, 119.42, 57.49, 57.06, 29.64, 28.82,
and 22.27. HRMS calculated for C21H24N4O2
2þBr–2 521.0188
[M–H]–; found: m/z 521.0189. HRMS calculated for C21H24N4O2
2þ
363.1888 [M–H]þ; found: m/z 363.1886.
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7-Carbamoyl-1-(5-(2-((hydroxyimino)methyl)pyridin-1-ium-1-yl)pen-
tyl)quinolin-1-ium bromide (14). 1-(5-Bromopentyl)-2-((hydroxyimi-
no)methyl)pyridin-1-ium bromide (736mg, 2.09mmol) and
quinoline-7-carboxamide (300mg, 1.74mmol) were dissolved in
DMF (17mL). The reaction mixture was stirred at 85 C for 144 h.
Acetone was poured into the reaction mixture and kept in
refrigerator overnight. The solid was filtered and washed with
acetone to give the desired product (143mg, 16%). 1H NMR
(500MHz, DMSO-d6) d 13.19 (s, 1H), 9.65 (dd, J¼ 5.9, 1.5 Hz, 1H),
9.34 (d, J¼ 8.3 Hz, 1H), 9.05 (dd, J¼ 6.3, 1.4 Hz, 1H), 8.93–8.83 (m,
1H), 8.77 (s, 1H), 8.67–8.62 (m, 1H), 8.60–8.46 (m, 2H), 8.42 (td,
J¼ 8.4, 1.4 Hz, 2H), 8.27 (dd, J¼ 8.4, 5.7 Hz, 1H), 8.10 (ddd, J¼ 7.8,
6.2, 1.6 Hz, 1H), 8.04 (s, 1H), 5.16 (t, J¼ 7.6 Hz, 2H), 4.73 (t,
J¼ 7.6 Hz, 2H), 2.18–1.99 (m, 2H), 1.92–1.87 (m, 2H), and 1.59–1.39
(m, 2H). 13C NMR (125MHz, DMSO-d6) d 165.90, 150.80, 147.11,
146.76, 145.99, 145.22, 141.38, 139.75, 137.16, 131.07, 130.85,
128.26, 127.45, 125.85, 123.33, 117.73, 57.46, 57.06, 29.62, 28.85,
and 22.30. HRMS calculated for C21H24N4O2
2þBr–2 521.0188
[M–H]–; found: m/z 521.0187. HRMS calculated for C21H24N4O2
2þ
363.1888 [M–H]þ; found: m/z 363.1885.
2.2. In vitro assays
2.2.1. Preparation and purification of cholinesterases
The hrAChE and hrBChE were prepared as recombinant proteins
at the University of Hradec Kralove. For their production, the
mammalian expression system was used. Briefly, the DNA
sequence encoding human AChE and BChE was obtained from
UniProtKB Server (www.uniprot.org, accession numbers: P22303
and P06276) and de novo synthesised as GeneArt Strings DNA
fragments by GeneArt Gene Synthesis Service (Thermo Fisher
Scientific, Waltham, MA). The DNA fragments were PCR-amplified
using gene-specific primers, adding the DNA sequence for C-ter-
minal 6His-tag. The amplicons were inserted into the mamma-
lian pcDNA3.4 vector by TOPO cloning technology, and the final
DNA constructs were verified by Sanger sequencing (ABI PRISM
3130xl). For protein expression, the DNA constructs were transi-
ently transfected into Hek293 derivatives. Recombinant proteins
were collected from culture supernatant six days later and stored
at 80 C for further purification.
The hrAChE and hrBChE were purified using NGC Medium-
Pressure Chromatography System (Bio-Rad, Hercules, CA)18. The
total volume of 6–8mL of medium containing secreted protein
was desalted using 5mL HiTrap Desalting column (GE Healthcare,
Chicago, IL) equilibrated with buffer A (20mM sodium phosphate
buffer, 150mM NaCl, 15mM imidazole, and 20% glycerol; pH 7.4).
Acquired supernatant was loaded onto a 1mL HisTrap FF column
(GE Healthcare, Chicago, IL) equilibrated with buffer A. The cap-
tured proteins were eluted with buffer B (20mM sodium phos-
phate buffer, 150mM NaCl, 500mM imidazole, and 20% glycerol;
pH 7.4). Imidazole was subsequently removed by repeated centri-
fugation in Amicon Ultra-4 (Ultracel-10K) tube (Merck Millipore,
Billerica, MA). Protein concentration was determined by linearised
Bradford method adapted for 96-well plate.
2.2.2. Inhibition of cholinesterases
The catalytic activity of purified enzymes was determined by
standard Ellman method adapted for 96-well plates19. The reaction
mixture contained purified (uninhibited) hrAChE (70 ng/mL protein
final concentration) or hrBChE (220 ng/mL protein), tested oxime
in Na-phosphate buffer at required concentration (varying from
0.1mM up to 80 mM) and 500 mM 5,50-dithiobis-2-nitrobenzoic acid
(DTNB) in 20mM Na-phosphate buffer (pH 7.4). This mixture was
pre-incubated at 37 C for 15min. Further, substrate acetylthiocho-
line iodide (ATChI) or butyrylthiocholine iodide (BTChI) were
added when their final concentrations in the mixture were
1000 mM (the final volume was 100 mL). The catalytic activity was
evaluated for further 10min at 37 C as amount of product (5-
thio-2-nitrobenzoic acid, TNB) formed by enzyme spectrophoto-
metrically at 436 nm using Spark multimode microplate reader
(Tecan, M€annedorf, Switzerland). The intrinsic inhibitory activity of
individual oximes (represented by IC50 values) towards hrAChE or
hrBChE was determined by non-linear regression using GraphPad
Prism 8.2 (GraphPad Software, La Jolla, CA).
2.2.3. Reactivation screening
4-Nitrophenyl isopropyl methylphosphonate (NIMP, sarin surro-
gate; >95%), 4-nitrophenyl ethyl methylphosphonate (NEMP, VX
surrogate, >95%), and 4-nitrophenyl ethyl dimethylphosphorami-
date (NEDPA, tabun surrogate, >95%) were purchased commer-
cially from Chemforase (Mont-Saint-Aignan, France). The
ethylparaoxon (POX, >99%) was purchased from Merck (Prague,
Czech Republic). The purified hrAChE or hrBChE was inhibited by
25 mM NIMP, NEMP, NEDPA, or POX for 30min in order to obtain
>99% inhibition. The excess of OP was removed by dialysis
against 25mM Na-phosphate buffer (pH 7.4) for 16 h (three buffer
exchanges) at 4–6 C. The enzymatic activity of purified (uninhib-
ited) hrAChE as a control or inhibited hrAChE was evaluated prior
or post dialysis to ensure that it had minimal influence towards
uninhibited or inhibited enzyme (Figure S1; Supplementary infor-
mation). The OP-inhibited enzyme was incubated for 15min with
100 or 10 mM solution of tested oxime. The reaction mixture con-
sisted of 10 mL of inhibited enzyme (1.95 ng of total protein),
20 mL of 2.5mM DTNB, 10 mL of corresponding oxime solution,
and 50 mL of 25mM Na-phosphate buffer (pH 7.4). The reaction
was started by addition of 10 mL of 10mM substrate ATChI or
BTChI (final volume was 100 mL). The catalytic activity of reacti-
vated enzyme was measured spectrophotometrically at 436 nm
using Spark multimode microplate reader (Tecan, M€annedorf,
Switzerland).
2.2.4. Reactivation kinetics
Selected compounds with promising reactivation ability were fur-
ther analysed in order to obtain reactivation kinetics parameters.
Inhibited enzyme was incubated in eight different times (varying
from 0.5 to 60min) with seven different concentrations of tested
oxime (varying from 5 to 800 mM) spectrophotometrically at
436 nm using Spark multimode microplate reader (Tecan,
M€annedorf, Switzerland). Acquired data were analysed by non-lin-
ear regression analysis according to Worek et al.20 using GraphPad
Prism 8.2 (GraphPad Software, La Jolla, CA).
2.3. Computational methods
The three-dimensional ligand structures were built with the Corina
online tool (Molecular Networks GmbH, Erlangen, Germany &
Altamira). Oximes were prepared in the anionic form. Before dock-
ing, atom types and protonation states of ligand structures were
checked and Gasteiger-Marsili charges were assigned using Sybyl-
X 1.1 (Tripos, St. Louis, MO). All proteins used in the docking stud-
ies were prepared with ProteinPrepare web service (pH 7.4, with-
out water molecules, including heteroatoms in pKa calculation)
21.
Docking studies were divided into three parts. In the first part, the
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inhibition of AChE and BChE by oximes was performed on mouse
apo enzymes, i.e. AChE (PDB code: 1J06) and human BChE (PDB
code: 1P0I) with the Gold Suite 5.3 (The Cambridge
Crystallographic Data Centre, Cambridge, UK). The binding site
was defined with all amino acid residues within 15 Å from the ser-
ine of the catalytic triad. A standard set of genetic algorithm
parameters with a population size of 100 and a number of opera-
tions of 100,000 was applied. As a result, 10 ligand conformations
were obtained and sorted according to the values of scoring func-
tion – GoldScore.
The second part, the interactions of oximes during the creation
of non-reactivating complexes with AChE and BChE inhibited by
OPs (VX, sarin, paraoxon) were performed with AChE complexes
(PDB codes: 2Y2V, 2Y2U, and 5HF5) and human BChE (PDB code:
3DJY) with oximes transferred from AChE complexes. Docking was
conducted with the Gold v5.3 program using analogical docking
parameters to those applied in the first part of the studies. In the
third stage, previously used protein complexes were modified and
the conformations of the OPs in them correspond to the sarin
conformation observed in the 5FPP complex. Docking studies
were performed with the SkeleDock web service to map the pre-
reactivation position of the pyridinium oxime fragment observed
in the 5FPP complex with asoxime22. Final poses were optimised
and rescored with the Gold v5.3 program (The Cambridge
Crystallographic Data Centre, Cambridge, UK). During rescoring,
the binding site was defined with all amino acid residues within
15 Å from the serine of the catalytic triad. Rescoring was per-
formed with the GoldScore scoring function. All results were
visualised by PyMOL 0.99rc2 (DeLano Scientific LLC, Palo Alto, CA).
3. Results and discussion
3.1. Molecular design and synthesis
Pyridinium-2-carbaldoximes (e.g. pralidoxime 1, asoxime 3) and
pyridinium-4-carbaldoximes (e.g. obidoxime 2) are known to
effectively reactivate OP-inhibited AChE. Their reactivation proper-
ties are given by 2- or 4-positioned oxime moiety, which has pKa
7.4–8.0 and it allows efficient formation of oximate anion at pH
7.4 in human organism23. However, their reactivation of OP-inhib-
ited BChE was found limited24. Their analogues with 4-positioned
oxime and pyridinium-4-carboxamide moiety (e.g. K027, K048,
K203, and K868) were described to have similar effectiveness for
certain OP-inhibited AChE and valuable carboxamide binding in
the AChE peripheral site16,25. However again, their reactivation of
OP-inhibited BChE was rather limited with exception of K86817.
But a decade ago, there were promising charged oximes found
for AChE or BChE reactivation (K117 and K127, Figure 2) that were
highlighted for tabun inhibited-BChE and recently showed slightly
increased brain penetration in mice14,26,27.
In this study, the molecular fragments of promising AChE and
BChE reactivators were incorporated in one molecule (Figure 2).
First, oxime moiety was retained in position 2 on the pyridinium
scaffold to decrease pKa for effective reactivation similarly to 1 or
3. Second, the quinolinium amide moiety was used for binding
into PAS of AChE similarly to K-oximes or for binding within more
spacious BChE active site28. In addition, the linker consisting of
five methylene units was implemented as a fragment for valuable
AChE or BChE reactivation similarly to K117 and K127, but opti-
mally with a weaker inhibition of both enzymes28–30.
The pyridinium-2-carbaldoximes with quinolinium carboxamide
moiety (4–8) were prepared in three step synthesis (Scheme 1).
First, the corresponding quinolinium carboxamide was synthesised
from its carboxylic acid using in situ acyl halide formation. Second,
pyridine-2-carbaldoxime was treated with dibromopentane to
form monocharged salt in acetonitrile (MeCN). Finally, the prod-
ucts were prepared by attaching the quinolinium carboxamides in
DMF and characterised.
3.2. In vitro inhibition and reactivation
The prepared compounds and standards were first tested on
hrAChE and hrBChE inhibition (Tables 1 and 2) to determine their
intrinsic inhibitory ability. The hrAChE in the solution was used for
in vitro screening purposes as a model of human AChE that is
mostly membrane bound in the neuronal tissues. The hrBChE in
the solution was used as model of human BChE from plasma. The
standard oximes were found weak inhibitors of both enzymes. In
contrast, the novel compounds resulted as low mM inhibitors of
hrAChE with exception of oxime 11 (IC50 18 mM). Plus, they
showed low to high inhibition of hrBChE with oximes 11 and 13
(IC50 45 mM) being the less potent BChE inhibitors. The lower
BChE inhibition is valuable to retain BChE scavenging function to
bind OP while OP-BChE adduct can be further reactivated. As
such, BChE in combination with BChE reactivator can detoxify
multiple OP molecules.
The reactivation screening was done on hrAChE and hrBChE
inhibited by nerve agent surrogates (NIMP – sarin surrogate,
NEMP – VX surrogate, NEDPA – tabun surrogate) and pesticide
metabolite paraoxon (POX). The nerve agent surrogates were used
for safety reasons, when they produce the same cholinesterase
adducts as the real nerve agents, but they have decreased tox-
icity31. The dialysis method was used to remove the excess of OP
Scheme 1. Synthesis of novel pyridinium-2-carbaldoximes with quinolinium carboxamide moiety.
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agent from the OP-inhibited enzyme. The conditions of used dialy-
sis protocol (4–6 C, pH 7.4) ensured the minimal ageing of OP
moiety bound to active site of the enzyme32. For reactivation of
hrAChE, obidoxime (2) was found to be the best reactivator for
NIMP, NEDPA, and POX, while asoxime (3) resulted as the lead
compound in case of NEMP inhibition. The best reactivation
among novel compounds was found for oxime 11, which was
able to restore hrAChE inhibited by all tested OPs, while the other
novel compounds were found ineffective. The higher reactivation
presented by compound 11 is most probably related to its lower
AChE inhibition when compared to other tested oximes.
For reactivation of hrBChE, pralidoxime (1), obidoxime (2), and
asoxime (3) resulted very closely in reactivation of NIMP or NEMP
at higher concentration (100 mM). However, only obidoxime (2)
showed particular reactivation of NIMP-hrBChE and negligible
reactivation of NEMP-hrBChE in one order of magnitude lower
concentration (10 mM). Further, two novel compounds 11 and 13
were found to effectively reactivate NIMP- and NEMP-hrBChE.
Interestingly, the reactivation of both novel oximes was compar-
able with obidoxime for NIMP-hrBChE at 10 mM, and compound
13 resulted as best oxime for reactivation of NEMP-hrBChE at
10 mM. Again, both compounds resulted as weaker BChE inhibitors
and better reactivators when compared to the other novel oximes
in the series. There was found minimal reactivation of NEDPA- or
POX-ihrBChE by all tested oximes.
Based on reactivation screening, the reactivation kinetics was
further determined for all standards (1–3), compound 11 in case
of hrAChE and compounds 11 and 13 in case of hrBChE (Tables 3
and 4, Figure 3). The affinity of oximes towards OP-inhibited
enzymes (reflected by KD) and their ability to remove the phos-
phyl residue from the active site of the enzyme (reflected by the
reactivity constant kr) were determined, when the specific overall
second-order reactivation rate constants (kr2¼kr/KD) were
calculated.
In case of NIMP- and NEMP-hrAChE, asoxime (3) resulted with
the highest kr2 followed by obidoxime (2). Compound 11 was
found better to pralidoxime (1) for NIMP- and NEMP-hrAChE in
contrast to reactivation screening of NEMP-hrAChE at 100 mM. For
NEDPA-hrAChE, obidoxime (2) showed highest kr2 followed by
asoxime (3) and oxime 11, which resulted again better to prali-
doxime (1). Notably, oxime 11 was found to have the highest
overall reactivation constant for POX-hrAChE followed by obidox-
ime (2), which is in contrast to its reactivation screening results at
both concentrations.
In case of NIMP- and NEMP-hrBChE, obidoxime (2) showed the
best kr2 values for both inhibitors, whereas pralidoxime (1) and
asoxime (3) resulted with markedly lower overall reactivation rate
constants. Interestingly, oximes 11 and 13 kr2 values were found
better to pralidoxime (1) and asoxime (3) for NIMP-hrBChE, plus
oxime 11 resulted better for NEMP-hrBChE, but in all cases slightly
worse to obidoxime (2).
To sum up the in vitro reactivation data for the novel com-
pounds, oxime 11 showed some reactivation of hrAChE inhibited
by all tested OP surrogates and POX, when in exhibited the high-
est overall reactivation rate for POX-hrAChE among all tested reac-
tivators. Oximes 11 and 13 showed some reactivation of hrBChE
inhibited by NIMP or NEMP, when oxime 11 resulted with the
best overall reactivation rate, although worse to obidoxime (2).
Based on these data, the molecular modelling study was per-
formed to reveal interactions of novel oximes with intact or inhib-
ited AChE or BChE with particular attention to oximes 11 and 13.
3.3. Molecular modelling
3.3.1. Acetylcholinesterase and butyrylcholinesterase inhibition
In molecular modelling experiments, all tested compounds
(10–14) proved to be stronger cholinesterase inhibitors than used
standards (1–3) with the most powerful inhibitor 14 (Figure 4)
and the weakest inhibitor 11 for both enzymes. The inhibition
potency was inversely correlated with the ability to reactivate
enzymes blocked by OPs. In the case of AChE, more potent inhibi-
tors (12–14) showed very consistent binding mode in the docking
studies. The crucial interactions for compound binding were
formed by oxime moiety within the oxyanion hole (GLY121,
Table 1. Reactivation screening of hrAChE inhibited by nerve agent surrogates and paraoxon.
Compound PAS ligand
hrAChE hrAChE reactivation (%)
IC50±CI95% (mM)
NIMP± SD NEMP± SD NEDPA± SD POX± SD
100 mM 10 mM 100 mM 10 mM 100 mM 10 mM 100 mM 10 mM
pralidoxime (1) – 629 ± 35.9 44.4 ± 0.6 10.7 ± 0.4 28.3 ± 0.9 4.5 ± 0.4 26.4 ± 0.1 4.3 ± 0.5 36.6 ± 0.5 5.6 ± 0.1
obidoxime (2) Pyr-4-CH¼NOH 330 ± 38.0 72.5 ± 3.3 54.4 ± 3.7 57.7 ± 2.1 11.5 ± 1.2 49.5 ± 4.7 31.7 ± 0.9 94.9 ± 1.6 34.5 ± 1.6
asoxime (3) Pyr-4-CONH2 145 ± 11.8 63.3 ± 3.2 43.7 ± 1.3 88.2 ± 6.8 24.2 ± 1.2 22.6 ± 1.8 2.6 ± 0.2 21.8 ± 2.8 2.3 ± 0.3
KR-26351 (10) Quin-3-CONH2 2.31 ± 0.5 6.1 ± 0.1 7.3 ± 0.77 5.0 ± 0.2 4.3 ± 0.2 5.9 ± 0.3 9.0 ± 0.7 7.3 ± 0.7 12.4 ± 1.0
KR-26352 (11) Quin-4-CONH2 18.3 ± 1.6 15.8 ± 0.2 14.3 ± 1.0 10.0 ± 0.6 6.2 ± 0.1 13.9 ± 1.0 21.4 ± 1.2 21.0 ± 2.74 23.2 ± 1.1
KR-26353 (12) Quin-5-CONH2 1.52 ± 0.3 4.5 ± 0.1 3.6 ± 0.3 1.7 ± 0.2 1.7 ± 0.6 2.4 ± 0.2 4.0 ± 0.2 5.6 ± 1.0 6.9 ± 0.9
KR-26354 (13) Quin-6-CONH2 1.08 ± 0.3 8.0 ± 0.7 9.9 ± 1.2 5.3 ± 0.4 8.2 ± 0.8 4.7 ± 0.2 9.3 ± 1.1 4.7 ± 0.7 9.8 ± 1.3
KR-26355 (14) Quin-7-CONH2 0.37 ± 0.2 1.6 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 0.7 ± 0.6 1.7 ± 0.4 1.5 ± 0.5 3.0 ± 1.1 2.3 ± 0.5
Table 2. Reactivation screening of hrBChE inhibited by nerve agent surrogates and paraoxon.
hrBChE reactivation (%)
hrBChE NIMP± SD NEMP± SD NEDPA± SD POX± SD
Compound PAS ligand IC50±CI95% (mM) 100 mM 10 mM 100 mM 10 mM 100 mM 10 mM 100 mM 10 mM
pralidoxime (1) – >3500 55.8 ± 1.4 15.2 ± 0.7 29.5 ± 0.4 6.5 ± 0.3 9.6 ± 0.7 1.30 ± 0.1 2.9 ± 0.7 0.4 ± 0.2
obidoxime (2) Pyr-4-CH¼NOH 760± 41.0 53.2 ± 3.5 27.1 ± 0.9 25.1 ± 0.4 9.1 ± 0.2 12.1 ± 0.4 3.50 ± 0.6 4.9 ± 0.2 1.2 ± 0.2
asoxime (3) Pyr-4-CONH2 1363 ± 260.0 45.9 ± 0.5 14.0 ± 0.8 20.7 ± 0.5 3.6 ± 0.2 3.8 ± 0.5 1.00 ± 0.6 3.8 ± 0.7 0.7 ± 0.4
KR-26351 (10) Quin-3-CONH2 15.03 ± 2.4 13.6 ± 2.2 12.0 ± 1.1 9.5 ± 0.2 8.4 ± 0.7 6.3 ± 0.9 2.8 ± 1.0 5.0 ± 0.04 1.0 ± 0.3
KR-26352 (11) Quin-4-CONH2 44.93 ± 3.6 33.3 ± 0.6 24.7 ± 0.5 26.5 ± 2.5 23.4 ± 1.2 9.5 ± 0.1 – 7.5 ± 1.0 –
KR-26353 (12) Quin-5-CONH2 6.58 ± 2.0 2.8 ± 0.6 3.7 ± 0.3 5.8 ± 0.9 5.0 ± 0.2 – – 1.0 ± 0.6 –
KR-26354 (13) Quin-6-CONH2 44.73 ± 4.3 23.9 ± 0.1 22.3 ± 0.4 22.2 ± 0.5 5.9 ± 0.2 0.5 ± 0.1 – – –
KR-26355 (14) Quin-7-CONH2 0.61 ± 0.2 11.8 ± 0.6 3.5 ± 0.2 3.5 ± 0.9 0.8 ± 0.4 – – 4.4 ± 1.0 –
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Table 3. Reactivation kinetics of hrAChE inhibited by nerve agent surrogates and paraoxon by selected oximes.


























pralidoxime (1) 102.7 0.889 8.66 87.22 1.024 11.74 51.89 0.151 2.92 97.04 1.039 10.71
obidoxime (2) 36.05 2.554 70.85 54.68 2.456 44.92 33.98 2.181 64.18 30.50 1.883 61.74
asoxime (3) 9.274 0.685 73.89 15.28 1.356 88.74 12.32 0.537 43.60 164.50 0.104 0.63
KR-26352 (11) 8.654 0.216 24.95 10.56 0.313 29.59 33.48 0.486 14.50 7.86 0.567 72.48
KD: phosphylated enzyme-oxime dissociation constant; kr: first-order reactivation rate constant; kr2: second-order reactivation rate constant (kr2¼kr/KD).
Table 4. Reactivation kinetics of hrBChE inhibited by NIMP, NEMP, and paraoxon by selected oximes.
Compound
NIMP-hrBChE NEMP-hrBChE
KD (mM) kr (min
–1) kr2 (mM
–1 min–1) KD (mM) kr (min
–1) kr2 (mM
–1 min–1)
pralidoxime (1) 415.60 1.891 4.55 827.2 3.257 3.94
obidoxime (2) 81.29 2.065 25.40 147 2.898 19.71
asoxime (3) 227.80 1.052 4.62 176.1 1.475 8.38
KR-26352 (11) 12.81 0.170 13.27 15.59 0.175 11.21
KR-26354 (13) 5.31 0.044 8.29 28.11 0.078 2.76




























Figure 3. Comparison of overall reactivation rate constants (kr2) of inhibited hrAChE and hrBChE.
Figure 4. Binding mode of the 14 (marked in green) within AChE and BChE active site.
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GLY122, and ALA204) as well as cation–p interactions created by
the pyridinium moiety with TRP86 and p–p stacking between qui-
nolinium fragment and TYR341. The differences in the position of
the amide moiety affect the compound interaction with the per-
ipheral anionic site (PAS). Substitution in position 6 (13) and 7
(14) promoted the creation of hydrogen bonds with SER293,
PHE295, and ARG296. When the amide group was in position 3
(10), hydrogen bonds were formed instead of a cation–p inter-
action with TYR341. And the amide group in position 5 (12) did
not form hydrogen bonds that could enhance interaction with the
enzyme. The substitution in position 4 (11) also led to the lack of
hydrogen bond formation by the amide group. Moreover, this
moiety caused steric hindrance which weakened the interaction of
the quinolinium system with TRP341. In contrast the AChE, the
entrance to the BChE active site is more spacious which is related
to less aromatic amino acids in this region in the case of BChE33.
This fact causes the differences both in the inhibition ability and
in the binding mode of the tested compounds within cholinester-
ases. For all tested compounds, it was observed that the oxime
fragment was bound close to the oxyanion hole of the BChE
(GLY115, GLY116, and ALA199) where it created several hydrogen
bonds. Moreover, the quinolinium fragment of compounds cre-
ated cation–p and p–p interactions with TRP82. Similarly to the
AChE, the position of the amide group modulated the inhibitory
ability of the compounds. For the most potent inhibitor 14, amide
moiety created hydrogen bonds with two amino acids TYR332
and ASP70. The weakest inhibitor 11 still presented interactions
with the oxyanion hole but there was found only p–p stacking
between quinoline and TRP82 with one additional hydrogen bond
created by carboxamide oxygen atom and GLY115.
3.3.2. Reactivation cycle analysis
In the theoretical studies on the cholinesterase reactivation, it is
crucial to understand, how the oxime compound can interact with
the catalytic site of ChE inhibited by OP at the molecular level. In
the reactivation cycle proposed by Allgardsson et al.34, the system
can evolve in two ways after the creation of an initial complex.
The first path leads to the formation of a pre-reactivation com-
plex, a next reactive conformation, and as a consequence, to the
reactivated enzyme. The creation of a pre-reactivation complex
was captured in the crystal structure of Mus musculus AChE
(mAChE)–sarin complex with asoxime (PDB code: 5FPP). The
second path leads to the creation of a non-reactive conformation
which prevents the compound from performing a nucleophilic
attack on OP adduct. Figure 5 shows the relation between these
two complexes. For our analysis, we assumed the existence of a
balance between the formation of the pre-reactivation and non-
reactive complex. We assumed that the equilibrium state between
these conformations reflects the effectiveness of reactivating
oxime. Analysing the results of the virtual docking via reflecting
both conformations, we wanted to indicate potential molecular
aspects that might determine the increased or decreased reactiva-
tion ability of the individual compounds.
The non-reactive conformations of oxime reactivators can be
found in many crystal structures (PDB codes: e.g. 2WHP, 5HFA,
and 5FPP). Similar poses were also observed during our docking
studies with both novel and standard oximes to the OP-AChE and
OP-BChE adducts.
The non-reactive binding modes of obidoxime (2) and asoxime
(3) from docking to AChE were analysed and we observed a sig-
nificant similarity in their docking results. The recurring p–p stack-
ing and cation–p interactions between the pyridine ring
connected to oxime moiety and aromatic TRP86 residue seemed
to be crucial for obidoxime and asoxime binding within AChE
active site. The arrangement of these standard oximes was add-
itionally stabilised by hydrogen bonds between the oxime moiety
and GLY120. The main difference between compounds 2 and 3
was found in their interactions with amino acids within the
entrance to the enzyme. In the case of obidoxime, regardless of
which OP compound was bound to AChE, the second pyridinium
fragment interacted with TYR337 (cation–p interactions) and
ASP74 (ionic interactions). In the case of asoxime in the AChE-VX
complex, we observed a hydrogen bond between the amide
group and the main chain of ASP74. Differently, compound 11 in
a non-reactive arrangement preferred to interact via the
Figure 5. The balance between the pre-reactivation complex (left) and non-reactive complex (right) as exemplified by the interaction of asoxime with sarin-inhibited
cholinesterase.
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quinolinium system with TRP86 (Figure 6). However and in
diversely from the standard compounds 2–3, these interactions
were found weaker and limited to the cation–p interactions.
Pyridine ring connected with the oxime moiety of 11 was found
to be located within the entrance to the enzyme active site, inter-
acting with TRP286, TYR72, and slightly less often with ASP74 or
TYR337. All described poses are presented in Figure 2(S)
(Supplementary information).
The next step of our analysis was focussed on the oxime con-
formation in the pre-reactivation state referring to that observed
in the crystal structure (PDB code: 5FPP)34. Using the position of
pyridinium moiety with oxime of asoxime as a template we repro-
duced the pre-reactivation position of the tested reactivators. It
allowed us to check which of the novel compounds was the best
suited to the protein when the reactivation process began. The
results of the standard compounds 2 and 3 brought many inter-
esting observations. Most importantly, the poses of individual
oximes in the pre-reactivation complexes with sarin-, VX-, and
POX-inhibited AChE indicated the existence of repetitive interac-
tions with particular amino acids (Figure 3(S)). The asoxime (3)
exhibited the largest number of interactions in a complex with
sarin-inhibited AChE. These were p–p stacking and cation–p inter-
actions with TYR341, the CH-p interaction with TYR124 and p–p
stacking with TRP286. A slight shift of asoxime position was
observed in the complex with VX-AChE and it led to weaker inter-
action with TYR124. In the POX-AChE adduct, such shifted position
was even more apparent and it prevented the formation of aro-
matic interactions with TYR124 and TRP286. The lack of interac-
tions with particular amino acids may explain the observed
decline in asoxime reactivation ability for POX-inhibited hrAChE
(Table 1). In contrast to asoxime, the number of specific interac-
tions for obidoxime (2) was only slightly changed. The previously
mentioned interactions occurred with the additional ionic inter-
action with ASP74 presented in all OP-AChE adducts. In the case
of POX-AChE, the cation–p interaction with TYR72 was observed.
These findings were consistent with the results of in vitro experi-
ments in which obidoxime (2) maintained the high reactivation
ability for all tested OP-AChE adducts.
The most active from the prepared compounds (oxime 11,
Figure 7) showed the highest number of interactions with the
AChE inhibited by sarin and POX. During the docking into the VX-
AChE adduct, specific interactions were limited to p–p stacking
and cation–p interactions with TYR341 and CH-p with TRP286.
Such decrease in the amount of specific interactions could be the
reason for the observed decline in the reactivation ability of 11
against VX (Table 1).
We conducted an analogous analysis for compounds reactivat-
ing BChE blocked by sarin and VX, and compared them to the
obidoxime (2). The BChE active site is larger than that of AChE.
Differences are most visible within the PAS. However and despite
the enzymatic differences, the binding mode of obidoxime within
the BChE active site was closely similar to that observed with
AChE. The p–p stacking and cation–p interactions with TRP82 and
TYR332 were observed in the most poses obtained during oxime
docking of OP-BChE complexes. All described interactions are pre-
sented in Figure 4(S).
The binding mode in the non-reactive complex for reactivators
11 and 13 with BChE did not change significantly when compared
to AChE even though PAS of BChE does not contain aromatic resi-
dues corresponding to TRP286 and TYR72 from AChE (Figure 8).
The p–p stacking and cation–p interactions with TRP82 and
TYR332 were still dominant. Moreover, ASP70 was involved in
ionic interactions with both compounds. The only exception was
the result obtained for 11 and the VX-BChE adduct when none of
the 10 docking runs established a pose corresponding to that for
VX-AChE. The highest-scored pose shown in Figure 8 indicated
that the compound 11 was bound at the entrance to the active
site of the enzyme. In this case, the quinolinium moiety interacted
with TYR332 by p–p stacking and cation–p interactions. Further,
the quinolinium moiety created an ionic bond with ASP70. The
oxime-containing fragment only formed a single hydrogen bond
with the ASN289 backbone.
In the next step, we have obtained pre-reactivation poses of
OP-BChE adducts via an analogous way to that for AChE. First, the
binding mode of obidoxime (2) was evaluated. The p–p stacking
with TYR332 and ionic bond with ASP70 were the common inter-
actions observed for sarin and VX-inhibited BChE. For sarin-BChE
adduct, the additional hydrogen bonds between the second (neu-
tral) oxime group of obidoxime and LEU273 and ALA277 at the
entry to the enzyme cavity were formed. Docking results of obi-
doxime with the VX-BChE adduct did not show these additional
interactions (Figure 5(S)).
Further, the poses for compounds 11 and 13 within the BChE
active site inhibited by sarin and VX were obtained (Figure 9).
Notably, the recurring interactions to cation–p and p–p stacking
with TYR332 were found decreased for both molecules. Plus fur-
ther loss of binding to ASP70 in a pre-reactivation state might be
the reason for the decreased reactivation ability of hrBChE by
these compounds compared to obidoxime (Table 1). A molecular
fragment that differed these two oximes from each other was the
hydrogen bond formed by the amide group. This bond with
ASN68 for sarin-BChE and ASN289 for VX-BChE adduct was more
Figure 6. The non-reactive poses of compound 11 obtained during docking to AChE inhibited by sarin (NIMP), VX (NEMP), and POX complexes.
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common in the docking poses of compound 11. This is in line
with the differences in the reactivation ability in vitro which was
found slightly better for oxime 11.
To sum up molecular modelling studies, they enabled to visual-
ise the significant differences between two states occurring during
enzymatic reactivation. The tested oximes were presented prefer-
ably in the conformations that did not lead to OP reactivation. On
this basis, it can be concluded that shifting the balance towards
the creation of the pre-reactivation complex is essential for effect-
ive reactivation of both AChE and BChE. Significantly lower values
of the scoring function during the evaluation of BChE pre-reactiva-
tion complexes with sarin and VX (compared to AChE) emphasised
the great difficulty to effectively reactivate this enzyme. Several
key amino acid residues repeatedly participated in the formation
Figure 7. The pre-reactivation poses of compound 11 in AChE blocked by sarin (NIMP), VX (NEMP), and POX.
Figure 8. The non-reactive binding mode of compounds 11 and 13 at the BChE active site blocked by sarin (NIMP) and VX (NEMP).
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of the pre-reactivation complex with oximes. Among them,
TYR332 and ASP70 in BChE or with TYR341, ASP74, and TRP286 in
AChE were highlighted. The significant impact of some of these
amino acids in the reactivation process was also confirmed in
mutagenesis studies35,36. For this reason, the shift of balance in
favour of pre-reactivation complex and consequent reactivation
should be done via increased interactions with these particular
amino acids. The introduction of the quinolinium fragment
improved interaction with the broadened entry into the BChE cav-
ity but this fragment significantly increased the potential for new
compounds to act as cholinesterase inhibitors as well. It seems
that further modifications in the length of the linker between the
pyridinium and quinolinium part and the introduction of substitu-
ents (that could reduce the quinolinium preference for interaction
with TRP86 in AChE or TRP82 in BChE) can both influence
unwanted enzyme inhibition and intensify pre-reactivation
formation.
4. Conclusions
The pyridinium-2-carbaldoximes with quinolinium carboxamide
moiety were designed and successfully prepared as the analogues
of formerly studied AChE reactivators (i.e. asoxime, K117, and
K127). The novel compounds showed intermediate-to-high inhib-
ition ability of both cholinesterases with compound 11 being the
less potent inhibitor. Their reactivation ability was evaluated
in vitro on hrAChE and hrBChE inhibited by nerve agent surro-
gates or pesticide metabolite paraoxon. In the reactivation screen-
ing, compound 11 was able to simultaneously reactivate hrAChE
inhibited by all used OPs and two novel compounds (11 and 13)
were able to reactivate hrBChE inhibited by NIMP or NEMP. The
determination of reactivation kinetics disclosed compound 11 that
was proved to be excellent reactivator of POX-inhibited hrAChE
better to obidoxime and showed increased reactivation of hrBChE
inhibited by NIMP or NEMP, although slightly worse to obidoxime.
The molecular interactions of studied reactivators were identified
by in silico calculations. Molecular modelling results revealed the
importance of creation of the pre-reactivation complex that could
lead to better reactivation of both cholinesterases together with
reducing particular amino acid interactions for lower intrinsic
inhibition of cholinesterases by the oxime.
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